Among those, β3-adrenergic receptor agonist (such as isoproterenol) and the activators of Pparγ (such as rosiglitazone) have been widely used for treating obesity and type 2 diabetes through the browning-related modification in carbohydrate and lipid metabolism [31,32]. Here, PPARG is linked to type 2 diabetes mellitus.